A Joint International Society for Pharmacoepidemiology (ISPE) – International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Special Task Force has reported on good practice for reporting real world evidence for healthcare decision-making. Real world evidence is defined as being obtained from real word data. Real world data is defined as being data obtained outside the context of randomized controlled trials and includes data from retrospective or prospective observational studies and observational registries.
The House of Commons Library have produced a briefing on the use of surgical mesh implants. The briefing summarises the uses of mesh implants and the statistics on procedures and complications. It also outlines the regulation around the use of mesh implants, the different reviews that have been undertaken, and parliamentary and legal discussion on the issue. The briefing was prepared in advance of a House of Commons debate on surgical mesh implants.
Public Health England (PHE) commissioned York Health Economics Consortium (YHEC) to develop an economic tool to compare the return on investment of interventions for the prevention of musculoskeletal (MSK) conditions. The tool focuses on high volume MSK conditions in working age adults (osteoarthritis hip and knee, back pain and neck pain) and compares the cost effectiveness of a selected number of interventions.
A POSTnote has been issued by the UK Parliamentary Office of Science and Technology describing the new EU Clinical Trial Regulation and the timetable for implementation. The POSTnote also examines options for UK regulation of clinical trials post-Brexit.
The NIHR highlighted the SUSPEND study as part of Urology Awareness Month. The study was published in the Lancet journal in 2015 and the NIHR news release states that the results of the SUSPEND study have changed practice across most urology departments in the UK and led to changes in the European Association of Urology guidelines for managing ureteric stones. Chris Harding, NIHR Clinical Research Network Sub-Specialty Lead for Benign Urology, said that the “study has changed urology treatment across the UK and internationally”. HERU were involved in the SUSPEND trial which found that the two drugs in the trial, tamsulosin and nifedipine, were unlikely to be cost-effective in the management of ureteric stones in hospitalised adults.
The National Institute for Health Research (NIHR) Signals website has highlighted the PROSPECT study (PROlapse Surgery: Pragmatic Evaluation and randomised Controlled Trials) which HERU researchers were involved in. The trial informed the Scottish Government review on transvaginal mesh implants and the Signal summarises NHS policy on mesh implants and assesses the PROSPECT trial.
A blog post from the Office of Health Economics summarises the current situation on the use of the EQ-5D-5L value set, highlights the recent NICE decision and explains and discusses the differences between the EQ-5D-5L and the EQ-5D-3L. It also discusses future research and policy positions.
The published research paper is also available and is discussed in the Academic Health Economists’ Blog.
Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics. 2017;1–16.